XML 47 R32.htm IDEA: XBRL DOCUMENT v3.24.0.1
Long-Term Investments (Tables)
 12 Months Ended
Dec. 31, 2023
Long-Term Investments [Abstract]  
Schedule of Ownership Percentages of Each Investee The ownership percentages of each investee are listed as follows:
   Ownership percentage    
   December 31,   December 31,   Accounting
Name of related party  2023   2022   treatments
Braingenesis Biotechnology Co., Ltd.   0.17%   0.17%  Cost Method
Genepharm Biotech Corporation   0.67%   0.67%  Cost Method
BioHopeKing Corporation   5.90%   5.90%  Cost Method
BioFirst Corporation   18.68%   15.51%  Equity Method
Rgene Corporation   26.65%   26.65%  Equity Method
Schedule of Extent the Investee Relies The extent the investee relies on the company for its business are summarized as follows:
Name of related party   The extent the investee relies on the Company for its business  
Braingenesis Biotechnology Co., Ltd.   No specific business relationship
Genepharm Biotech Corporation   No specific business relationship
BioHopeKing Corporation   Collaborating with the Company to develop and commercialize drugs
BioFirst Corporation   Loaned from the investee and provides research and development support service
Rgene Corporation   Collaborating with the Company to develop and commercialize drugs

 
Schedule of Long-Term Investment Long-term investment mainly consists of the following:
   December 31,
2023		   December 31,
2022		 
Non-marketable Cost Method Investments, net        
Braingenesis Biotechnology Co., Ltd.  $7,213   $7,169 
Genepharm Biotech Corporation   22,021    21,887 
BioHopeKing Corporation   818,018    813,014 
Subtotal   847,252    842,070 
Equity Method Investments, net          
BioFirst Corporation(a)   1,680,488    
-
 
Rgene Corporation(b)   
-
    
-
 
Total  $2,527,740   $842,070 
Schedule of Balance Sheet Balance Sheet
   December 31,
2023		   December 31,
2022		 
Current Assets  $1,451,877   $1,543,151 
Non-current Assets   686,206    739,472 
Current Liabilities   2,286,058    2,663,051 
Non-current Liabilities   347,193    103,447 
Stockholders’ Equity   (495,168)   (483,874)
   December 31,
2023		   December 31,
2022		 
Current Assets  $50,538   $68,302 
Non-current Assets   250,716    303,893 
Current Liabilities   2,591,960    2,478,868 
Non-current Liabilities   811    2,441 
Shareholders’ Deficit   (2,291,517)   (2,481,309)
Schedule of Statement of Operation Statement of operation
   Year Ended
December 31,		 
   2023   2022 
Net sales  $734   $30,162 
Gross profit   289    8,239 
Net loss   (1,194,797)   (1,274,539)
Share of losses from investments accounted for using the equity method   (221,888)   
-
 

 

   Year Ended
December 31,		 
   2023   2022 
Net sales  $
         -
   $
        -
 
Gross Profit   
-
    
-
 
Net loss   (291,522)   (1,550,123)
Share of loss from investments accounted for using the equity method   
-
    
-
 
Schedule of Loss on Investment in Equity Securities The components of loss on investment in equity securities for each period were as follows:
   Year Ended
December 31,		 
   2023   2022 
Share of equity method investee losses  $(221,888)  $
       -